AU771754B2 - Prophylactic dietary supplement based on milk - Google Patents
Prophylactic dietary supplement based on milk Download PDFInfo
- Publication number
- AU771754B2 AU771754B2 AU57192/00A AU5719200A AU771754B2 AU 771754 B2 AU771754 B2 AU 771754B2 AU 57192/00 A AU57192/00 A AU 57192/00A AU 5719200 A AU5719200 A AU 5719200A AU 771754 B2 AU771754 B2 AU 771754B2
- Authority
- AU
- Australia
- Prior art keywords
- milk
- dietary supplement
- casein
- diabetes
- casomorphin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 235000013336 milk Nutrition 0.000 title claims description 165
- 210000004080 milk Anatomy 0.000 title claims description 165
- 239000008267 milk Substances 0.000 title claims description 150
- 235000015872 dietary supplement Nutrition 0.000 title claims description 67
- 230000000069 prophylactic effect Effects 0.000 title description 4
- 239000005018 casein Substances 0.000 claims description 107
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 98
- 206010012601 diabetes mellitus Diseases 0.000 claims description 85
- 239000000047 product Substances 0.000 claims description 63
- 235000019152 folic acid Nutrition 0.000 claims description 52
- 239000011724 folic acid Substances 0.000 claims description 50
- 235000021240 caseins Nutrition 0.000 claims description 49
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 47
- 229960000304 folic acid Drugs 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 44
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 42
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 42
- 208000019553 vascular disease Diseases 0.000 claims description 37
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 35
- 241000283690 Bos taurus Species 0.000 claims description 33
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 27
- 229940011671 vitamin b6 Drugs 0.000 claims description 21
- 229960003237 betaine Drugs 0.000 claims description 19
- 230000029087 digestion Effects 0.000 claims description 18
- 201000010193 neural tube defect Diseases 0.000 claims description 18
- 235000008160 pyridoxine Nutrition 0.000 claims description 18
- 239000011677 pyridoxine Substances 0.000 claims description 18
- 208000035581 susceptibility to neural tube defects Diseases 0.000 claims description 18
- 235000005911 diet Nutrition 0.000 claims description 17
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 14
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 241000282414 Homo sapiens Species 0.000 claims description 11
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 10
- 210000004204 blood vessel Anatomy 0.000 claims description 9
- 230000000378 dietary effect Effects 0.000 claims description 9
- 230000007850 degeneration Effects 0.000 claims description 8
- 230000036039 immunity Effects 0.000 claims description 8
- 239000002243 precursor Substances 0.000 claims description 8
- 230000002519 immonomodulatory effect Effects 0.000 claims description 7
- 239000013589 supplement Substances 0.000 claims description 7
- 230000001900 immune effect Effects 0.000 claims description 5
- 230000036470 plasma concentration Effects 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000007547 defect Effects 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 210000000276 neural tube Anatomy 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 5
- 239000003643 water by type Substances 0.000 claims 1
- 102000011632 Caseins Human genes 0.000 description 85
- 108010076119 Caseins Proteins 0.000 description 85
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 49
- 235000021247 β-casein Nutrition 0.000 description 37
- 235000013365 dairy product Nutrition 0.000 description 29
- 108090000765 processed proteins & peptides Proteins 0.000 description 28
- 230000000694 effects Effects 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 18
- 229940021722 caseins Drugs 0.000 description 11
- 208000029078 coronary artery disease Diseases 0.000 description 11
- 235000020247 cow milk Nutrition 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 238000007792 addition Methods 0.000 description 10
- 235000020189 fortified milk Nutrition 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 230000037213 diet Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 208000019622 heart disease Diseases 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- RKYJTDSQXOMDAD-JKXTZXEVSA-N (2s,3s)-2-[[(2s)-1-[2-[[(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1N(C(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CC=2C=CC(O)=CC=2)CCC1 RKYJTDSQXOMDAD-JKXTZXEVSA-N 0.000 description 4
- 206010016880 Folate deficiency Diseases 0.000 description 4
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 4
- 108010011756 Milk Proteins Proteins 0.000 description 4
- 201000010829 Spina bifida Diseases 0.000 description 4
- 208000006097 Spinal Dysraphism Diseases 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 229940014144 folate Drugs 0.000 description 4
- 235000015243 ice cream Nutrition 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 235000013618 yogurt Nutrition 0.000 description 4
- 101000741065 Bos taurus Beta-casein Proteins 0.000 description 3
- ADBHAJDGVKLXHK-UHFFFAOYSA-N Casomorphin Chemical compound CCC(C)C(C(O)=O)NC(=O)C1CCCN1C(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)C1N(CCC1)C(=O)C(N)CC=1C=CC(O)=CC=1)CC1=CC=CC=C1 ADBHAJDGVKLXHK-UHFFFAOYSA-N 0.000 description 3
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 108010020546 beta-casomorphin 7 Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000013351 cheese Nutrition 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000013322 soy milk Nutrition 0.000 description 3
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 3
- 235000019158 vitamin B6 Nutrition 0.000 description 3
- 239000011726 vitamin B6 Substances 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000005593 Endopeptidases Human genes 0.000 description 2
- 108010059378 Endopeptidases Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000002302 brachial artery Anatomy 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229940066758 endopeptidases Drugs 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 150000002224 folic acids Chemical class 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000000945 opiatelike Effects 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 235000008476 powdered milk Nutrition 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283699 Bos indicus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 101100010343 Drosophila melanogaster lobo gene Proteins 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 206010048707 Homocystinaemia Diseases 0.000 description 1
- 206010020365 Homocystinuria Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 description 1
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101150034459 Parpbp gene Proteins 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- IALSFJSONJZBKB-HRCADAONSA-N Pro-Tyr-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@@H]3C(=O)O IALSFJSONJZBKB-HRCADAONSA-N 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000031708 Saprospiraceae Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000145 adjuvantlike effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000020535 bottled fortified water Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000001326 carotid sinus Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N cystathionine Chemical compound OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001904 diabetogenic effect Effects 0.000 description 1
- 235000020930 dietary requirements Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000014105 formulated food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 235000020603 homogenised milk Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000020191 long-life milk Nutrition 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000030364 neural tube closure defect Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000020200 pasteurised milk Nutrition 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 235000019220 whole milk chocolate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ336505 | 1999-06-29 | ||
NZ33650599 | 1999-06-29 | ||
NZ50405700 | 2000-04-18 | ||
NZ504057 | 2000-04-18 | ||
PCT/NZ2000/000116 WO2001000047A1 (en) | 1999-06-29 | 2000-06-29 | Prophylactic dietary supplement based on milk |
Publications (2)
Publication Number | Publication Date |
---|---|
AU5719200A AU5719200A (en) | 2001-01-31 |
AU771754B2 true AU771754B2 (en) | 2004-04-01 |
Family
ID=26652075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU57192/00A Expired AU771754B2 (en) | 1999-06-29 | 2000-06-29 | Prophylactic dietary supplement based on milk |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1196047A4 (zh) |
JP (1) | JP2003503038A (zh) |
CN (1) | CN1159984C (zh) |
AU (1) | AU771754B2 (zh) |
WO (1) | WO2001000047A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI114538B (fi) * | 2001-01-12 | 2004-11-15 | Finnfeeds Finland Ltd | Glysiinibetaiinin käyttö verenpainetta alentavan tuotteen valmistukseen |
WO2003055335A1 (en) * | 2001-12-21 | 2003-07-10 | Dsm Ip Assets B.V. | Modified methionine rich food products and process for their manufacture |
KR20130020939A (ko) * | 2002-07-03 | 2013-03-04 | 에이2 코포레이션 리미티드 | 우유의 지방산 조성을 변경시키는 방법 |
US20060280802A1 (en) * | 2002-10-04 | 2006-12-14 | Campbell Julie H | Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2 |
MX2011010454A (es) | 2009-04-03 | 2012-01-25 | Nestec Sa | Mejoramiento en la promocion de la sana recuperacion del crecimiento. |
EP2745709A1 (en) * | 2012-12-24 | 2014-06-25 | Abbott Laboratories, Inc. | Nutritional compositions with reduced beta-casein a1 and related methods |
CN105407971B (zh) * | 2013-05-31 | 2020-11-17 | 艾尔牛奶有限公司 | β-酪蛋白A2和肠炎症的预防 |
MX368912B (es) * | 2013-07-12 | 2019-10-21 | A2 Milk Co Ltd | Beta-caseína a2 y reducción y prevención de síntomas de intolerancia a la lactosa. |
RU2698794C2 (ru) * | 2013-08-23 | 2019-08-30 | Зэ А2 Милк Компани Лимитед | Бета-казеин а2 и уровень глюкозы в крови |
CN104940205A (zh) * | 2015-06-03 | 2015-09-30 | 华中科技大学 | 蝶酰谷氨酸在防治环境内分泌干扰物致子代糖尿病中的应用 |
MX2018007819A (es) * | 2015-12-22 | 2018-12-17 | A2 Milk Co Ltd | Formula infantil que comprende peptidos de leche humana. |
JP6256888B2 (ja) * | 2016-02-29 | 2018-01-10 | 高知県公立大学法人 | 健脳食品または健脳飲料およびこれらを投与する方法 |
AU2016424981B2 (en) * | 2016-09-30 | 2021-11-04 | The A2 Milk Company Limited | Beta-caseins and gut microbiota |
CN115553340A (zh) * | 2022-10-18 | 2023-01-03 | 北大荒完达山乳业股份有限公司 | 一种具有提高免疫力功能的降敏牛奶及其制备方法 |
CN115708530A (zh) * | 2022-11-15 | 2023-02-24 | 北大荒完达山乳业股份有限公司 | 一种促进消化舒适性并稳定血糖的孕产妇配方奶粉及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997034497A1 (en) * | 1996-03-15 | 1997-09-25 | Niva Shapira | Dairy products |
WO1999003365A1 (en) * | 1997-07-14 | 1999-01-28 | N.V. Nutricia | Nutritional composition containing methionine |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MC2041A1 (fr) * | 1988-06-24 | 1990-05-30 | Johannes Cornelius Str Andries | Agents anti-atherogenic |
WO1996036239A1 (en) * | 1995-05-16 | 1996-11-21 | Corran Norman Stuart Mclachlan | Food product and process |
US5668173A (en) * | 1996-02-23 | 1997-09-16 | The Board Of Trustees Of The University Of Illinois Corp. | Method of increasing the conversion of homocysteine to methionine and uses thereof |
US6008221A (en) * | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
US5993866A (en) * | 1997-09-12 | 1999-11-30 | Shapira; Niva | Process of making food products having reduced methionine ratios |
PT951842E (pt) * | 1999-01-20 | 2003-04-30 | Nutricia Nv | Formula de alimento adaptada para bebe |
-
2000
- 2000-06-29 CN CNB008098174A patent/CN1159984C/zh not_active Expired - Lifetime
- 2000-06-29 EP EP00942589A patent/EP1196047A4/en not_active Withdrawn
- 2000-06-29 AU AU57192/00A patent/AU771754B2/en not_active Expired
- 2000-06-29 JP JP2001505772A patent/JP2003503038A/ja active Pending
- 2000-06-29 WO PCT/NZ2000/000116 patent/WO2001000047A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997034497A1 (en) * | 1996-03-15 | 1997-09-25 | Niva Shapira | Dairy products |
WO1999003365A1 (en) * | 1997-07-14 | 1999-01-28 | N.V. Nutricia | Nutritional composition containing methionine |
Also Published As
Publication number | Publication date |
---|---|
AU5719200A (en) | 2001-01-31 |
CN1159984C (zh) | 2004-08-04 |
EP1196047A1 (en) | 2002-04-17 |
JP2003503038A (ja) | 2003-01-28 |
EP1196047A4 (en) | 2004-12-22 |
WO2001000047A1 (en) | 2001-01-04 |
CN1368853A (zh) | 2002-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU771754B2 (en) | Prophylactic dietary supplement based on milk | |
TWI400082B (zh) | 用於改進嬰兒學習及/或記憶行為的嬰兒配方 | |
Auestad et al. | Dairy bioactive proteins and peptides: a narrative review | |
US20220125093A1 (en) | Nutritional supplements including meal replacements and related methods | |
JP6026720B2 (ja) | 血糖値降下剤及び血糖値降下飲食品組成物 | |
Miller et al. | Casein: a milk protein with diverse biologic consequences | |
JP2008533208A (ja) | 糖耐性を改善するためのアミノ酸組成物 | |
MX2011010454A (es) | Mejoramiento en la promocion de la sana recuperacion del crecimiento. | |
Hambraeus et al. | Nutritional aspects of milk proteins | |
AU2005332128B2 (en) | Food composition for stimulating growth comprising fraction isolated from mammalian colostrum or milk whey | |
ES2918577T3 (es) | Péptidos recientemente identificados para uso en la inducción de tolerancia oral | |
JP4394155B2 (ja) | 脂質代謝改善剤 | |
AU2002321557B2 (en) | Use of leptin for infant with low birth weight for prevention of obesity | |
Lemon | Protein and amino acids | |
AU2007247025B2 (en) | Use of alpha-lactalbumin for regulation of glycemia | |
Tiwari et al. | Nutritional Values and Therapeutic Uses of Capra hircus Milk. | |
NZ516712A (en) | Prophylactic dietary supplement based on milk | |
AU2016348517B2 (en) | Method for inducing satiety | |
Williams | Clinical syndromes of copper deficiency | |
Clifton et al. | Effect of glycomacropeptides (GMP) on satiety hormones and food intake | |
Wood | Goat’s vs cow’s milk consumption: Analysis of feeding behaviour, brain activation and gene expression in laboratory animals | |
Ranade et al. | Milk derived casomorphins and their health significance: A review | |
CN107708433B (zh) | 用于在幼年哺乳动物中诱导和维持口服耐受性的致耐受性肽与tfg-b的组合 | |
TW202402190A (zh) | 包含源自乳清蛋白的肽的生長促進用組合物 | |
JP2020005598A (ja) | 起床時コルチゾール濃度調節用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |